Studies of P2X ATP Receptors
P2X ATP 受体的研究
基本信息
- 批准号:7152000
- 负责人:
- 金额:$ 31.82万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2001
- 资助国家:美国
- 起止时间:2001-03-01 至 2009-11-30
- 项目状态:已结题
- 来源:
- 关键词:ATP ReceptorsAgonistAnimalsArchitectureBacterial InfectionsBindingBinding SitesBiochemicalBladderBladder ControlBloodBlood ClotBlood PlateletsBlood coagulationBrainBurn injuryCalciumCellsChromosome PairingClassCoupledDataDevelopmentEjaculationEndothelial CellsFamilyFamily memberFunctional disorderGTP-Binding ProteinsGastrointestinal tract structureGene FamilyGenesGenomeGlutamate ReceptorGlycine ReceptorsGoalsHair CellsHepatocyteHumanIndividualInjuryInvertebratesKnock-outKnowledgeLeukocytesLigand BindingLungMolecularMonitorMovementMusMutationMyocardiumNervous system structureNeuraxisNeurogliaNeuronal InjuryNeuronsNeurotransmittersNicotinic ReceptorsNumbersOxygenP2X-receptorPainPerceptionPeripheralPeripheral Nervous SystemPersistent painPhenotypePhylogenetic AnalysisPhysiological ProcessesPhysiologyPlayProcessProteinsPurinoceptorRangeRattusResearch PersonnelRoleSignal TransductionSkeletal systemSorting - Cell MovementSpecificityStructureSynapsesTestingTissuesUrinationZinccell motilityfightinggastrointestinalin vivomemberreceptorresearch studyresponse
项目摘要
DESCRIPTION (provided by applicant): The P2X proteins are ATP gated channels that depolarize cells and also allow calcium to enter. P2X receptors are expressed in virtually every tissue, including neurons and glia of the central and peripheral nervous system, smooth, skeletal and cardiac muscle, cochlear hair cells, platelets, most classes of white blood cells, hepatocytes, and endothelial cells in the lung and gastrointestinal tract. The importance of members of this gene family for normal physiology is apparent from the range of phenotypes that are seen in their absence, Mice in which specific P2X receptors are knocked out show dysfunction in pain perception, ability to void the bladder, gut motility, neuronal control of ejaculation, the ability of the nervous system to monitor the oxygen level in the blood, the ability to fight bacterial infection, and blood clotting. A major problem in the purinergic receptor field is the limited specificity of agonists and antagonists that can be used to alter ATP signaling in vivo. The goal of the experiments described here is to better characterize the molecular mechanisms that allow ATP and allosteric modulators to open P2X receptor channels. The results of these studies should facilitate the development of agents that act more specifically on particular receptors. We will use electrophysiological, biochemical, and molecular approaches to study receptors bearing complementary mutations in adjacent or non-adjacent subunits. The specific aims are: Goal 1 - To test whether the zinc binding sites that modulate channel activity in P2X2, P2X3, and P2X4 receptors are within or between subunits, and to define residues that participate in these binding sites. We will also define our understanding about the mechanisms by which zinc promotes channel opening in P2X2 receptors. Goal 2 - To test whether the ATP binding site of P2X receptors is within or between subunits and to define additional residues that are exposed in the ATP binding pocket. These experiments will also test the number of molecules of ATP that must be bound in order to open a channel. Goal 3 - To define the molecular movements that are a consequence of zinc or ATP binding to P2X2 receptors. These experiments are of particular relevance to making progress in understanding and treating pain associated with tissue injury, as P2X2 and P2X3 receptors have been implicated as playing essential roles as sensing the damage and signaling the central nervous system. Having a better understanding of the structure of these receptors should allow the development of new treatments for this type of pain, and so greatly ease the suffering of individuals with burns and other injuries that produce persistent pain.
描述(由申请人提供):P2 X蛋白是ATP门控通道,可使细胞去活化并允许钙进入。P2 X受体在几乎所有组织中表达,包括中枢和外周神经系统的神经元和神经胶质、平滑肌、骨骼肌和心肌、耳蜗毛细胞、血小板、大多数类别的白色血细胞、肝细胞以及肺和胃肠道中的内皮细胞。该基因家族的成员对于正常生理学的重要性从其缺失时所见的表型范围是显而易见的。敲除特定P2 X受体的小鼠显示疼痛感知、排空膀胱的能力、肠道运动、射精的神经元控制、神经系统监测血液中氧水平的能力、对抗细菌感染的能力、和血液凝固。嘌呤能受体领域的一个主要问题是可用于改变体内ATP信号传导的激动剂和拮抗剂的特异性有限。本文所述实验的目的是更好地表征允许ATP和变构调节剂打开P2 X受体通道的分子机制。这些研究的结果应该有助于开发对特定受体更特异性地起作用的药物。我们将使用电生理学,生物化学和分子方法来研究在相邻或不相邻亚基中具有互补突变的受体。具体目标是:目的1 -测试调节P2 X2、P2 X3和P2 X4受体通道活性的锌结合位点是否在亚基内或亚基之间,并确定参与这些结合位点的残基。我们还将定义我们对锌促进P2 X2受体通道开放的机制的理解。目标2 -测试P2 X受体的ATP结合位点是否在亚基内或亚基之间,并确定暴露在ATP结合口袋中的其他残基。这些实验还将测试为了打开通道而必须结合的ATP分子的数量。目标3 -确定锌或ATP与P2 X2受体结合的分子运动。这些实验对于理解和治疗与组织损伤相关的疼痛具有特别的相关性,因为P2 X2和P2 X3受体被认为在感知损伤和向中枢神经系统发出信号方面发挥重要作用。更好地了解这些受体的结构应该允许开发这种类型疼痛的新治疗方法,从而大大减轻烧伤和其他产生持续疼痛的伤害的个体的痛苦。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
RICHARD IRWIN HUME其他文献
RICHARD IRWIN HUME的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('RICHARD IRWIN HUME', 18)}}的其他基金
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 31.82万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 31.82万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 31.82万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 31.82万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 31.82万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 31.82万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 31.82万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 31.82万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 31.82万 - 项目类别:
Fentanyl Addiction: Individual Differences, Neural Circuitry, and Treatment with a GLP-1 Receptor Agonist
芬太尼成瘾:个体差异、神经回路和 GLP-1 受体激动剂治疗
- 批准号:
10534864 - 财政年份:2023
- 资助金额:
$ 31.82万 - 项目类别: